Sector News

Sanofi culls ImmunoGen cancer drug from clinical pipeline

February 8, 2018
Life sciences

Sanofi has dropped an anticancer antibody-drug conjugate it licensed from ImmunoGen. The French pharma gained full control of the anti-LAMP1 drug as part of a recent deal but has now removed the asset from its pipeline.

ImmunoGen first teamed up with Sanofi to work on ADCs against the target in 2013. That deal gave the biotech a shot at generating up to $30 million in milestones. But last year it agreed to forego this potential source of income in favor of an upfront fee. The revised deal made Sanofi the fully paid-up owner of anti-LAMP1 drug SAR428926.

Any confidence that move implied in the drug has since evaporated. With an open label, 110-person advanced solid tumor trial nearing the end, Sanofi has dropped SAR428926 from its pipeline.

The ADC is one of seven drugs ditched by Sanofi in its latest quarterly results, although in several cases the company had already disclosed its plan to walk away from the assets.

Sanofi first revealed it was stopping development of a phase 3 Clostridium difficile vaccine late last year. And it snuck out news that it was ditching SAR156597 in idiopathic pulmonary fibrosis in November. SAR100842, another drug affected by the cull, was last seen in the clinic in 2014. And patisiran has fallen off the pipeline as a result of the revision of the agreement with Alnylam. All four assets are on the list of dropped drugs Sanofi included in its latest quarterly results.

New casualties disclosed in the filing include GZ402668 and isatuximab. Sanofi is closing in on the end of a single-ascending dose study of GZ402668 in patients with progressive multiple sclerosis. But the pipeline update states Sanofi won’t be taking the anti-CD52 monoclonal antibody forward in the relapsing form of the disease.

Anti-CD38 drug isatuximab has reached the end of the line as a monotherapy treatment of acute lymphoblastic lymphoma. A suite of clinical trials of the candidate in other indications will continue.

By Nick Paul Taylor

Source: Fierce Biotech

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”